[Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma].

Abstract:

:Glioblastoma multiforme still remains, at present, the most frequent and deadly primary malignant glioma in adult. Despite safer and larger neurosurgical resections, patients almost always relapse very close or inside the tumor bed. Since more than 20 years, radiation therapy (RT) continue delivering the same dose of 60 Gy in 6 weeks, more precisely guided with CT-scanner and magnetic resonance imaging (MRI) in the treatment position. If morbidity has decreased with "non whole-brain" volumes, RT is nearly always failing locally, as surgery. Until now, all the series evaluating escalating doses (up to 80-90 Gy) in limited volumes have failed. One can really question : is the good dose delivered in the adequate volume? Main goal of new imaging techniques is to better visualize microscopic extension of malignant glioma cells. As based on metabolic principles, areas of abnormalities visualized with functional imaging have a different meaning, often complementary from conventional data. The four evaluated techniques are : magnetic resonance spectroscoy (MRS), functional MRI (fMRI), 18FDG or methionine PET, IMT (123iodine-alpha-methyl-thyrosine) SPECT. Each technique has potential interests and limits, MRS and fMRI appearing the most promising : they have both acceptable spatial resolution and can be executed just after conventional MRI acquisition. Areas of functional abnormalities are only partially including areas of hyperintensity in T1, T2 weighted MRI. It is therefore highly possible that, using it complementary to conventional CT and MRI for RT treatment planning, they add some precious informations; consequently, the very limited efficacy/toxicity ratio could be increased. This hypothesis will only be confirmed by prospective studies registering in parallel both functional and morphological abnormalities, linking them with sites of local recurrence. Once "targeted" the real microscopically invaded areas, one can speculate on new escalating dose studies, delivering RT in "adequate" volumes, combining it with new "targeted" drugs, as already recently demonstrated in head and neck cancers.

journal_name

Bull Cancer

journal_title

Bulletin du cancer

authors

Dhermain F,Ducreux D,Bidault F,Bruna A,Parker F,Roujeau T,Beaudre A,Armand JP,Haie-Meder C

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

333-42

issue

4

eissn

0007-4551

issn

1769-6917

journal_volume

92

pub_type

杂志文章,评审
  • [Role of [18F]-FDG PET-CT in the management of the head and neck cancers].

    abstract:OBJECTIVES:To evaluate the impact of [(18)F]-FDG PET/CT image fusion in the management of carcinomas of the upper aero-digestive tract. METHODS:This retrospective study included 169 patients with squamous cell cacinoma of the upper aerodigestive tract who underwent a PET/CT for : initial staging (n = 47), cervical lym...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Fakhry N,Barberet M,Lussato D,Cammilleri S,Mundler O,Giovanni A,Zanaret M

    更新日期:2006-10-01 00:00:00

  • [Pharmacologic bases of chemotherapy of brain tumors in children].

    abstract::In terms of pharmacology, drug delivery is an important obstacle in the development of brain tumor chemotherapy. The blood-brain barrier limits the drug penetration in normal brain tissue around the tumor and at distant potential metastatic sites. In the tumor, the altered blood-brain barrier, ie blood-tumor barrier, ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Vassal G

    更新日期:1990-01-01 00:00:00

  • Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.

    abstract:OBJECTIVE:To assess the feasibility and efficacy of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) without adjuvant chemotherapy for relapsed or persistent advanced ovarian cancer. METHODS:This observational study included stage IIIC ovarian cancer patients due to undergo CRS...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2010.1063

    authors: Carrabin N,Mithieux F,Meeus P,Trédan O,Guastalla JP,Bachelot T,Labidi SI,Treilleux I,Rivoire M,Ray-Coquard I

    更新日期:2010-04-01 00:00:00

  • [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].

    abstract::Serotonin (5-Hydroxytryptamine) seems to play a dominant role in triggering vomiting induced by cytotoxic agents through the stimulation of 5-HT3 receptors. They have been observed in the GI tract as well as in the brain (area postrema). Ondansetron is a specific antagonist of 5-HT3 serotonin receptors. Its anti-emeti...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: d'Allens H,Aubert B,Bons J,Pappo M

    更新日期:1991-01-01 00:00:00

  • [Chemoradiotherapy and anal canal cancer].

    abstract::Local control and sphincter preservation are the two challenges of anal canal cancer treatment. These tumors are radio- and chemo-sensitive and treatment moved from surgical approach, with abdominoperineal resection, to definitive radiation therapy with or without concurrent chemotherapy. Randomised trials proved the ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Ortholan C,François E,Gérard JP

    更新日期:2005-12-01 00:00:00

  • [Cyclooxygenase 2 inhibitors and cancer chemoprevention].

    abstract::Chemoprevention is the use of natural or synthetic compounds in order to reverse, suppress or prevent the carcinogenic process. Among the many pathways dysregulated during the carcinogenic process, cyclooxygenase-2 (Cox2) seems to be one of the most promising pathways to target in order to achieve chemopreventive and ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Masmoudi A,Chevalier TL,Sabatier L,Soria JC

    更新日期:2004-05-01 00:00:00

  • [Pharmacological consequences of the targeting of epidermal growth factor receptor].

    abstract::Through clearly identified molecular mechanisms, EGFR targeting leads to cell physiology modifications as cell proliferation, apoptosis and DNA repair. These mechanisms can explain the proper activity of EGFR targeting drugs but also represent a strong rational basis on which several experimental studies have been des...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Milano G,Magné N

    更新日期:2003-11-01 00:00:00

  • [Value of thymidine kinase in the prediction of response to treatment by chemotherapy or hormone therapy in breast cancer].

    abstract::Thymidine kinase (TK) was assayed in the cytosol of 210 primary breast cancers to assess its predictive value for response to first line chemotherapy and hormonotherapy. We performed correlations between TK and the other prognosis factors of breast cancer. TK activity is correlated with SBR grading and estrogen recept...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Bennini N,Mauriac L,Wafflart J,Bonichon F,Durand M

    更新日期:1992-01-01 00:00:00

  • [Life style and occupational factors and prevention of second primary cancers after childhood and adolescent cancer: Current state of knowledge].

    abstract:CONTEXT:Survival of children, adolescents and young adults treated for cancer increased with improved treatments. But there is still an increased risk of second primary cancer (SPC) in the long term compared to the population of the same age, especially related to treatments. A reflection on the follow-up of this popul...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2015.03.017

    authors: Duval S,Carretier J,Boyle H,Philip T,Berger C,Marec-Bérard P,Fervers B

    更新日期:2015-07-01 00:00:00

  • [Importance of a multidisciplinary approach to metastatic cancer of the rectum].

    abstract::Management of rectal cancers with synchronous metastasis is difficult. We evaluated in 23 patients a combination of pelvic radiotherapy at the dose of 45 Gy in 5 weeks and 25 fractions with chemotherapy by 5-fluorouracil (350 mg/m2/day) and folinic acid (20 mg/m2/day) for 5 days at the time of the first and the fifth ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Mitry E,Pompili PL,Rougier P,Toma C,Ducreux M,Lusinchi A,Elias D,Fabri MC,Bourhis J,Kac J,Eschwege F,Lasser P

    更新日期:1998-08-01 00:00:00

  • [Early adjuvant intraportal chemotherapy with 5-fluorouracil after hepatic resection of colorectal metastasis: a preliminary clinical and pharmacokinetic study].

    abstract::Intraportal continuous infusion of 5-FU (600 mg/m2/24 h during 7 days) was administered in the immediate postoperative course of 6 consecutive patients with colorectal metastases resected for cure (one segmentectomy and 5 nonanatomical local resections). One month later, a systemic continuous infusion of 5-FU was deli...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Seitz JF,Aubert C,Giovannini M,Delpero JR,Houvenaeghel G,Guerinel G,Carcassonne Y

    更新日期:1989-01-01 00:00:00

  • [Frequency of cancer in France: 2004 update].

    abstract::The most recent cancer mortality and morbidity data available for France are presented. In 1999, cancers are the first cause of death among men (87,000 deaths) and the second most common among women (57,000 deaths) after cardiovascular diseases. Lung cancer is the most common cause of cancer death (21,000) in the male...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Hill C,Doyon F

    更新日期:2004-01-01 00:00:00

  • Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.

    abstract::The French Northern Oncology Group carried out a randomised, cross-over study comparing two anti-emetic treatment strategies in 150 chemotherapy-naive patients, receiving their first two courses of moderately-emetogenic drugs. Nausea and vomiting were assessed using a self-administered questionnaire for five days. Ant...

    journal_title:Bulletin du cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Bonneterre J,Hecquet B

    更新日期:1995-12-01 00:00:00

  • [Quality assurance in head and neck medical oncology].

    abstract::In medical oncology, how can we be sure that the right drug is being administered to the right patient at the right time? The implementation of quality assurance criteria is important in medical oncology, in order to ensure that the patient receives the best treatment safely. There is very little literature about qual...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2014.1968

    authors: Digue L,Pedeboscq S

    更新日期:2014-05-01 00:00:00

  • [Particle therapy: carbon ions].

    abstract::Carbon ion therapy is an innovative radiation therapy. It has been first proposed in the forties by Robert Wilson, however the first dedicated centres for human care have been build up only recently in Japan and Germany. The interest of carbon ion is twofold: 1) the very sharp targeting of the tumour with the so calle...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2010.1151

    authors: Pommier P,Hu Y,Baron MH,Chapet O,Balosso J

    更新日期:2010-07-01 00:00:00

  • [Standards, Options and Recommendations for non metastatic breast cancer patients].

    abstract:CONTEXT:The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of French Cancer Centers (FNCLCC), the 20 French Cancer Centers, and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of...

    journal_title:Bulletin du cancer

    pub_type: 指南,杂志文章,实务指引

    doi:

    authors: Mauriac L

    更新日期:2002-02-01 00:00:00

  • [Clinical value of the potential doubling time (Tpot) measured by flow cytometry].

    abstract::The potential doubling time (Tpot) is defined as the time necessary to double the number of proliferating tumor cells in the absence of spontaneous cell loss. Tpot is thought to be a better index of tumor proliferation than clinically observed tumour volume doubling time. The in vivo measurement of Tpot is a possible ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Dubray B,Maciorowsky Z,Cosset JM,Terry NH

    更新日期:1995-01-01 00:00:00

  • [Genetic counseling in cancerology].

    abstract::The evidence that genetic factors are of some importance in the etiology of cancer originates has been determined by genetic epidemiology, molecular biology, cytogenetics. Genetic counselling is one of the possible strategies for controlling cancer through genetics. Genetic counselling in this field more often concern...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Feingold J

    更新日期:1991-01-01 00:00:00

  • [Portal vein embolization: Present and future].

    abstract::Portal vein embolization consists of occluding a part of the portal venous system in order to achieve the hypertrophy of the non-embolized liver segments. This technique is used during the preoperative period of major liver resection when the future remnant liver (FRL) volume is insufficient, exposing to postoperative...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2017.03.009

    authors: Piron L,Deshayes E,Escal L,Souche R,Herrero A,Pierredon-Foulongne MA,Assenat E,le Lam N,Quenet F,Guiu B

    更新日期:2017-05-01 00:00:00

  • [Nice-Saint-Paul de Vence 2020 recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer].

    abstract::Endometrial cancer is a common cancer in older women and is often associated with comorbidities. Management of metastatic disease and/or relapse requires a multidisciplinary approach. Recent advances in the understanding of oncogenesis and molecular classification of endometrial cancers offer new therapeutic perspecti...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,实务指引

    doi:10.1016/j.bulcan.2020.06.006

    authors: Alexandre J,Le Frere-Belda MA,Prulhiere K,Treilleux I,Leary A,Pomel C,Chargari C,Ducassou A,Joly F,groupe ARCAGY-GINECO.

    更新日期:2020-10-01 00:00:00

  • [Access to fertility preservation for adolescents and young adults aged 15 to 24 years with cancers in Auvergne, France].

    abstract:INTRODUCTION:Cancers of adolescents and young adults have particular epidemiological specificities. The improvement in their survival should be accompanied by an increased consideration of the treatments' side effects, among which the potential decrease in fertility. The objective of the study was to describe the acces...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2020.03.013

    authors: Grèze V,Mechdoud S,Vorilhon S,Isfan F,Rouel N,Chaput L,Brugnon F,Kanold J

    更新日期:2020-01-01 00:00:00

  • [What are the expectations of coordination and accompaniment of French patients with cancer towards their community pharmacist?]

    abstract:PURPOSES:Analyze the relationship and expectations of cancer patients towards the community pharmacist in a pharmaceutical care coordination project. METHODS:In November 2014, a questionnaire was distributed to ambulatory patients of a university hospital specialized in oncology. Thirteen questions explored the consum...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2017.11.017

    authors: Hébert G,Minvielle E,Di Palma M,Lemare F

    更新日期:2018-03-01 00:00:00

  • [Hepatocellular carcinoma: Increase in incidence or future plague?]

    abstract::Hepatocellular carcinoma is the third most frequent cause of cancer death worldwide, particularly in Asia and Africa. Most cases complicate an underlying liver cirrhosis due to hepatitis B or C chronic virus infection or alcoholic abuse. But, following the current epidemics of obesity and type 2 diabetes, it appears t...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2018.02.003

    authors: Raoul JL,Raimbourg J,Hiret S,Adhoute X,Senellart H

    更新日期:2018-05-01 00:00:00

  • ARLTS1, potential candidate gene in familial aggregation of hematological malignancies.

    abstract:INTRODUCTION:Genetic predisposition to familial hematological malignancies was previously described through several epidemiological analyses, but the genetic basis remains unclear. The tumor-suppressor ARLTS1 gene was previously described in sporadic hematological malignancies and familial cancer context. METHODS:In t...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2016.10.016

    authors: Hamadou WS,Besbes S,Mani R,Bourdon V,Ben Youssef Y,Achour B,Regaieg H,Eisinger F,Mari V,Gesta P,Dreyfus H,Bonadona V,Dugast C,Zattara H,Faivre L,Noguchi T,Khélif A,Sobol H,Soua Z

    更新日期:2017-02-01 00:00:00

  • [What's new in the treatment of cancer pain?].

    abstract::Improvements have been made recently in the treatment of cancer pain. First of all, this symptom is better recognized and evaluated in cancer patients. Then new therapeutic options have became available in France : tramadol, WHO level II analgesic, for intermediate to severe pain; gabapentine, a new anticonvulsivant d...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Di Palma M,Poulain P,Pichard E

    更新日期:2004-01-01 00:00:00

  • [Biology of small-cell bronchogenic carcinoma: recent advances].

    abstract::In the last ten years considerable progress has been made in small-cell lung carcinoma (SCLC) biology, along with the technical progress made in molecular biology. This progress now allows us to propose a model for the genesis and the development of this type of tumor. Tobacco, the principal causal factor plays a dual...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Levy R,Andrieu JM,Even P

    更新日期:1992-01-01 00:00:00

  • [Thyroid carcinoma on struma ovarii: Diagnosis and treatment].

    abstract::Thyroid carcinoma on struma ovarii (TCSO) is a rare ovarian tumour, derivate from monodermic teratomas. It represents about 0.01% of overall ovarian tumours and 5 to 10% of struma ovarii. The diagnosis is histologic and retrospective after pelvic surgery; radiographic imaging being unspecific. Because of its rarity, t...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2017.11.014

    authors: Lebreton C,Al Ghuzlan A,Floquet A,Kind M,Leboulleux S,Godbert Y

    更新日期:2018-03-01 00:00:00

  • Image guided radiotherapy for prostate cancer.

    abstract::The purpose of external beam radiotherapy is to sterilize malignant tumours and at the same time to avoid complications by radiation injury to the surrounding healthy tissues. Modern radiation techniques in recent years have allowed to safely escalate the dose by approximately 10% for the treatment of prostate cancer,...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2008.0599

    authors: Soete G,Verellen D,Storme G

    更新日期:2008-03-01 00:00:00

  • [Juvenile nasopharyngeal carcinoma: anatomoclinic, biologic, therapeutic and evolutive aspects].

    abstract::Nasopharyngeal carcinoma (NPC) represents one of the most frequent epithelial tumours of the child in intermediate risk regions. In the Maghreb, it represents the first cancer of teenagers of 15-20 years old. The Epstein Barr virus (EBV) is the most important etiologic factor. Its role in the pathogeneses of NPC has b...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2010.1087

    authors: Toumi N,Frikha M,Siala W,Khabir A,Karray H,Boudawara T,Gargouri RM,Ghorbel M,Daoud J

    更新日期:2010-04-01 00:00:00

  • [Pertuzumab and solid tumors: perspectives].

    abstract::Over the past decade, trastuzumab was the only available monoclonal anti-HER2 antibody for the treatment of HER2 positive breast and gastric cancer. Recently, pertuzumab added to docetaxel and trastuzumab showed dramatic overall survival improvement in first line treatment of HER2 positive metastatic breast cancer. Pe...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2014.2026

    authors: Barthélémy P,Leblanc J,Wendling F,Wissler MP,Bergerat JP

    更新日期:2014-12-01 00:00:00